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Splicing regulation in spinal muscular atrophy by an RNA structure
formed by long‐distance interactions
Abstract
Humans carry two copies of the survival motor neuron gene: SMN1 and SMN2. Loss of SMN1 coupled with
skipping of SMN2 exon 7 causes spinal muscular atrophy (SMA), a leading genetic disease associated with
infant mortality. Our discovery of intronic splicing silencer N1 (ISS‐N1) is a promising target, currently in a
phase III clinical trial, for an antisense oligonucleotide–mediated splicing correction in SMA. We have
recently shown that the first residue of ISS‐N1 is locked in a unique RNA structure that we term ISTL1
(internal stem through long‐distance interaction–1). Complementary strands of ISTL1 are separated from
each other by 279 nucleotides. Using site‐specific mutations and chemical structure probing, we confirmed
the formation and functional significance of ISTL1. Located in the middle of intron 7, the 3′ strand of ISTL1
falls within an inhibitory region that we term ISS‐N2. We demonstrate that an antisense
oligonucleotide–mediated sequestration of ISS‐N2 fully corrects SMN2 exon 7 splicing and restores high
levels of SMN in SMA patient cells. These results underscore the therapeutic potential of the regulatory
information present in a secondary and high‐order RNA structure of a human intron.
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Splicing regulation in spinal muscular atrophy by a RNA 
structure formed by long distance interactions
Natalia N. Singh, Brian M. Lee, and Ravindra N. Singh
Department of Biomedical Sciences, Iowa State University, Ames, Iowa 50011, USA
Abstract
Humans carry two copies of Survival Motor Neuron gene: SMN1 and SMN2. Loss of SMN1 
coupled with skipping of SMN2 exon 7 causes spinal muscular atrophy (SMA), a leading genetic 
disease associated with infant mortality. Our discovery of intronic splicing silencer N1 (ISS-N1) is 
a promising target, currently in phase 3 clinical trial, for an antisense-oligonucleotide-mediated 
splicing correction in SMA. We have recently shown that the first residue of ISS-N1 is locked in a 
unique RNA structure that we term ISTL1 (Internal Stem Through Long-distance interaction-1). 
Complementary strands of ISTL1 are separated from each other by 279 nucleotides. Using site-
specific mutations and chemical structure probing we confirmed the formation and functional 
significance of ISTL1. Located in the middle of intron 7, the 3′ strand of ISTL1 falls within an 
inhibitory region that we term ISS-N2. We demonstrate that an antisense-oligonucleotide-
mediated sequestration of ISS-N2 fully corrects SMN2 exon 7 splicing and restores high levels of 
SMN in SMA patient cells. These results underscore the therapeutic potential of the regulatory 
information present in a secondary and high-order RNA structure of a human intron.
Introduction
Formation of RNA structure is essential for many steps in controlled gene expression, 
including regulation of alternative splicing.1–3 There is a growing acceptance of the role 
terminal stem-loop (TSL) structures play in modulating the accessibility of splice sites (ss).2 
Advancements in computational algorithms have allowed predictions of complex RNA 
structures. Often, multiple secondary structures could be predicted for the same transcript 
and the probability of structural variants increases with the increase in the size of the 
sequence. However, extracting the significance of a particular structure among multiple 
alternatives remains a daunting task. Consequently, it is still a mystery how the splicing 
machinery is guided by certain RNA structures to remove specific intronic sequences. In the 
absence of a simple method of structure determination in vivo, compensatory mutations 
combined with in vitro structure probing (chemical and/or enzymatic) provide evidence in 
support of an RNA structure that functions in splicing. Overall the process of structure 
validation remains an arduous endeavor with very limited studies available on probed RNA 
structures of large human pre-mRNAs.
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About half of all human genetic disorders are caused by mutations that alter pre-mRNA 
splicing.4 Growing evidence suggests that significant regulatory information is trapped in 
RNA structures of transcriptomes.5,6 Of note, ~40% of the human genome are intronic 
sequences.7 Hence, there is a need for developing functional assays that uncover the role of 
critical intronic RNA structures in regulation of pre-mRNA splicing. Here we describe a 
unique RNA structure formed by long-distance interactions (LDI) between intronic 
sequences within a critical gene associated with spinal muscular atrophy (SMA). SMA is the 
leading genetic disease of children and infants. Detailed aspects not covered in this report, 
such as SMA pathogenesis, demography of disease, mouse models of SMA and therapeutic 
approaches, have been described in recent reviews.8–14
Molecular basis of SMA
Humans have two nearly identical copies of the Survival Motor Neuron (SMN) gene: SMN1 
and SMN2.15 Two SMN genes code for identical proteins; however, due to skipping of exon 
7, SMN2 predominantly generates a shorter transcript, which is translated into a truncated, 
unstable protein.16,17 The inability of SMN2 to compensate for the loss of SMN1 results in 
SMA, a debilitating childhood disease.18 SMN is an essential housekeeping protein with 
multiple functions that include snRNPs biogenesis, transcription, translation, signal 
transduction, stress granule formation and macromolecular trafficking. Several recent 
reviews describe SMN functions in detail.10,11,19–21 Here we focus on the evolving 
mechanism of splicing regulation of SMN2 exon 7, since strategies aimed at the postnatal 
restoration of exon 7 inclusion in SMN2 have shown promise for SMA therapy.
SMN2 mutations associated with exon 7 skipping
A C-to-T mutation at the 6th position (C6U in transcript) of exon 7 and an A-to-G 
substitution at the 100th position (A100G) of intron 7 contribute towards skipping of SMN2 
exon 7 (Fig. 1).22,23 To explain the inhibitory effects of C6U, various mechanisms including 
loss of an enhancer associated with SF2/ASF, gain of a silencer associated with hnRNP A1 
and strengthening of a stem-loop structure (TSL1) at the 3′ ss of exon 7 have been proposed 
(Fig. 1).23–29 It has also been suggested that C6U creates an extended inhibitory context 
(Exinct) that encompasses most of the TSL1.50 Consistently, substitutions within Exinct/
TSL1 have been found to restore SMN2 exon 7 inclusion.
In vivo selection of the entire exon
To determine the impact of every single exonic residue on splicing, we performed an in vivo 
selection of the entire exon 7.25 Briefly, SMN1 minigene containing partially randomized 
exon 7 was transfected into human cervical carcinoma (C33a) cells. The purpose of partial 
randomization was to maintain the wild type characteristics of the exon while probing the 
position-specific significance of every residue within the 54-nt long exon 7.51 About 20 h 
posttransfection total RNA was isolated and reverse transcribed using oligo dT primer. 
Thereafter, exon 7-included transcripts were amplified using engineered primers 
encompassing restriction sites for re-cloning into SMN1 minigene splicing cassette. The 
process was repeated four times to enrich exon 7 sequences that favored inclusion of exon 7. 
About sixty unique sequences of exon 7 from the final selected pool were analyzed for 
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regulatory motifs. Exonic positions where wild-type residues were preserved were 
considered as positive, whereas, exonic positions where wild-type residues were substituted 
by non-wild type residues were considered as negative. Motifs were defined based on the 
clustering of the positive and the negative positions. Findings of in vivo selection validated 
the presence of Exinct and revealed another inhibitory region (3′-Cluster) at the end of exon 
7 (Fig. 1B).25 The middle portion of exon 7 was found to harbor a positive regulatory region 
termed Conserved tract (Fig. 1B). The above findings of in vivo selection were 
independently validated by an antisense-oligonucleotide (ASO)-based approach.52
The last position of exon 7 is an A residue. However, a non-wild type G residue (54G) was 
overwhelmingly selected at this position.25 Our subsequent experiments showed that 54G 
was able to fully restore SMN2 exon 7 inclusion even in the absence of several positive 
regulatory elements that were originally thought to be critical for exon 7 splicing. When we 
reported the significance of 54G, most studies focused on the 3′ ss of exon 7 due to its (3′ ss) 
close proximity to C6U mutation, which at the time was thought to be the primary cause of 
exon 7 skipping.53 The results of in vivo selection brought a new perspective to the field (of 
exon 7 splicing regulation) by demonstrating an intrinsic problem with the 5′ ss.25 This 
prompted us to further characterize the 5′ ss that is defined by the linear RNA sequence as 
well as RNA secondary structure at the junction of exon 7 and intron 7.
Weak 5′ ss as a limiting factor for exon 7 splicing
The strong stimulatory effect of 54G on SMN2 exon 7 splicing can be explained by 
improved recruitment of U1 snRNP to the 5′ ss due to the increase in the number of base 
pairs formed between U1 snRNA and the 5′ ss. It is also possible that the stimulatory effect 
of 54G is due to the disruption of a predicted stem-loop structure (TSL2) that sequesters the 
5′ ss of exon 7.24 Compensatory mutations and enzymatic structure probing validated the 
formation of TSL2. Also, mutations that disrupted TSL2, restored SMN2 exon 7 inclusion, 
confirming that the poor accessibility of the 5′ ss contributes to exon 7 skipping. Further 
validating that the 5′ ss of exon 7 is poorly defined, a mutant U1 snRNA that increased the 
base pairing with the wild type 5′ ss of exon 7 restored SMN2 exon 7 inclusion.24 Presence 
of the intronic splicing silencer N1 (ISS-N1) immediately downstream of the 5′ ss of exon 7 
provided an additional basis for the weak 5′ ss of this exon (Fig. 1D).43 Of note, the 15-nt 
long ISS-N1 is a portable cis-element predicted to harbor two hnRNP A1 motifs.43,47 
Deletion or an ASO-mediated sequestration of ISS-N1 promoted SMN2 exon 7 inclusion. 
ISS-N1 partially overlaps with an 8-nt long GC-rich sequence (GCRS), sequestration of 
which by an 8-mer ASO also promoted SMN2 exon 7 inclusion.44,54 Notably, ISS-N1 has 
emerged as the most tested antisense target for splicing correction in a human genetic 
disease.11 Currently, an antisense drug (ISIS-SMNRx) based on ISS-N1 target is undergoing 
phase 3 clinical trial by ISIS Pharmaceuticals.55
Role of transacting factors on SMN2 exon 7 splicing
Multiple factors, including SF2/ASF, hnRNP A1, Tra2-β1, hnRNP G, hnRNP Q, Sam68, 
and TIA1 have been implicated in regulation of SMN2 exon 7 splicing (Fig. 1). Most of the 
reported factors act through binding to exon 7. Tra2-β1 that directly interacts with exon 7 
and recruits SRp30c, hnRNP G and TDP-43 to exon 7 was initially thought to be critical for 
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exon 7 inclusion.32,56–58 However, latest observations in a Tra2-β1 knockout mouse support 
the dispensable nature of Tra2-β1 for SMN exon 7 splicing.59 Recently, Welander distal 
myopathy (WDM) patients carrying TIA1 mutations have been found to exhibit an enhanced 
rate of SMN exon 7 skipping.60 TIA1 is a glutamine (Q)-rich RNA-binding protein (QRDP) 
that is known to recruit U1 snRNP to the 5′ ss of exons.61,62 We have previously shown that 
TIA1 interacts with two U-rich clusters (URC1 and URC2) within intronic sequences 
downstream of ISS-N1 and that overexpression of TIA1 restores SMN2 exon 7 inclusion 
(Fig. 1D).49 PSF, another QRDP has been recently shown to promote SMN2 exon 7 
inclusion by binding to an exonic sequence that overlaps Tra2-β1 binding site.36 Out of four 
binding sites of hnRNP A1, three are located within intron 7 (Fig. 1D). While first two 
intronic binding sites of hnRNP A1 are located within ISS-N1, the third one is associated 
with SMN2-specific mutation at the 100th position of intron 7 (Fig. 1D).23,47 Of note, the 
role of many proteins shown to affect SMN2 exon 7 splicing in cell-based assays have not 
yet been validated in knockout mouse models and/or in patients.
Discovery of a unique LDI
For simplicity we define a LDI as any RNA:RNA interaction in which two distantly located 
sequences (or residues) are brought together by canonical or non-canonical base pairing. In 
certain situations, LDIs could be formed by residues separated form each other by thousands 
of nucleotides. LDI prediction as well as validation of their functional significance in pre-
mRNA splicing is quite challenging. We have recently reported the critical role of a unique 
RNA structure formed by LDIs within SMN2 intron 7.46 One of the defining aspects of our 
discovery is the ASO-based approach that uncovered the critical role of a cytosine residue at 
the 10th intronic position (10C) in the formation of this inhibitory RNA structure.45 The 
discovery of a 10C-mediated LDI is significant since it offers several antisense targets as 
potential therapies for SMA.
Functional assay leading to the discovery of LDI
While 10C is the first position of ISS-N1, it is also a part of GCRS that partially overlaps 
with ISS-N1.44 The structure-associated role of 10C was serendipitously discovered in an 
antisense microwalk in which two 14-nt long ASOs (F14 and L14) produced opposite 
effects on SMN2 exon 7 splicing (Fig. 2).45 While F14 promoted SMN2 exon 7 inclusion by 
sequestering the first 14 residues of 15-nt long ISS-N1, L14 promoted SMN2 exon 7 
skipping by sequestering the last 14 residues of ISS-N1. Substitutions or deletion of 10C or 
deletion of a deep intronic sequence in the 3′ half of intron 7 abrogated the inhibitory effect 
of L14.45 Therefore, we attributed the inhibitory effect of L14 to a LDI in which 10C 
interacts with downstream intronic sequences. To narrow down the exact site of the LDI, we 
made overlapping deletions throughout the intron 7 in an SMN2 minigene construct and 
compared the splicing pattern of these mutants in the presence and absence of L14. We 
identified a 6-nt long motif (GCAGAC) spanning the region from 290th to 295th positions of 
intron 7 as the interacting partner of 10C (Fig. 2).46 We named this motif the LDI Site 1 or 
LS-1. The entire LS-1 sequence was predicted to be engaged in the formation of an internal 
stem (RNA:RNA duplex) made by LDI. We termed this structure as an internal stem 
through LDI 1 or ISTL1 (Fig. 2). Confirming the association of ISTL1 with the inhibitory 
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effect of L14, mutations that disrupted ISTL1 fully eliminated the negative effect of L14 on 
exon 7 splicing. Interestingly, L14 does not interact with any of the residues that constitute 
ISTL1, since its annealing site is located downstream of ISTL1, and yet it (L14) exerts its 
negative effect on exon 7 splicing through ISTL1. These findings underscore an important 
but rarely observed phenomenon that the effect of an ASO could be executed indirectly 
through structures formed in the vicinity of the ASO annealing site.
Structure probing validated the formation of ISTL1
The formation of ISTL1 implicated the deep intronic sequence in influencing the decisions 
made at the 5′ ss of SMN2 exon 7. To confirm that ISTL1 is indeed formed, we probed the 
structure of the entire SMN2 intron 7 employing Selective 2′-Hydroxyl Acylation analyzed 
by Primer Extension (SHAPE) method.46 Among available methods of in vitro structure 
probing, SHAPE is a relatively unbiased technique that allows simultaneous interrogation of 
all residues within an RNA of interest.63 The structure probed by SHAPE confirmed the 
formation of ISTL1. ISTL2, ISTL3 and ISTL4 emerged as additional structures formed by 
LDIs (Fig. 3). The results of structure probing placed the first hnRNP A1 binding site 
associated with ISS-N1 within an internal loop between ISTL1 and TSL3 (Fig. 3).46 The 
second hnRNP A1 binding site associated with ISS-N1 constituted the 5′ stem of TSL3 (Fig. 
3). The hnRNP A1 motif at the 100th position of intron 7 was engaged in short internal stem 
formation (Fig. 3). According to the SHAPE analysis, URC1 and URC2 are located in 
double-stranded regions (Fig. 3). This structural arrangement is likely to prevent recruitment 
of TIA1 to these sites. Our experimentally derived structure did not support some of the 
predictions made for several regions of intron 7, including an Element 2-associated TSL 
located downstream of URC2.48 The results of the SHAPE analysis validated the formation 
of TSL2, although the U residue at the second intronic position (2U) was found to be 
accessible (Fig. 3). The accessibility of 2U could be due to co-axial stacking of bases at the 
junction of TSL2 and ISTL1.
Mechanism of ISTL1-mediated splicing regulation
ISTL1 is an 8 base-pair duplex with 50% GC-rich content. The 5′ strand of ISTL1 is 
separated from the 3′ strand by 279 residues (from 11th to 289th positions of intron 7). The 
distal end of the duplex is closed by a GC base pair formed between 10C and 290G, 
whereas, the proximal end of the duplex is closed by AU base pair formed between 3A and 
297U. The side-by-side positioning of TSL2 and ISTL1 fully sequesters the U1 snRNA-
annealing site at the 5′ ss of exon 7 (Fig. 4). Hence, ASOs that disrupt ISTL1 are likely to 
induce recruitment of U1 snRNP and stimulate SMN2 exon 7 inclusion. Based on the 
findings of structure probing in the presence of L14 and F14, we conclude that ISTL1 is 
stabilized and destabilized by L14 and F14, respectively.46 Interestingly, a major reduction 
in size of intron 7 by deletions from 93rd to 281st positions and from 330th to 412th positions 
of intron 7 stimulated SMN2 exon 7 inclusion.46 As per structure prediction these deletions 
do not disrupt ISTL1; they preserve the inhibitory effect of L14. Similarly, breaking of 
ISTL2 by three nucleotide deletions stimulated SMN2 exon 7 inclusion; note that in the 
presence of these deletions ISTL1 structure is predicted to be maintained and L14 remains 
inhibitory.46 The above result of deletion mutations suggests that the overall structural 
context of intron 7 has a stabilizing effect on ISTL1. However, since the stimulatory effect 
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of deletions could be due to the loss of negative elements and/or gain of positive elements, 
additional experiments will be required to assess the role of other structures on the stability 
of ISTL1. Our finding that L14 remains inhibitory in deletion mutants described above 
suggests that the stabilization of ISTL1 by L14 does not require most of the intronic 
structures. Our results also support that hnRNP A1/A2B1 and PTB proteins are not involved 
in the formation of ISTL1, since their depletion did not abrogate the inhibitory effect of 
L14.46 However, one cannot rule out the role of yet unknown proteins in ISTL1 formation/
stabilization.
LDIs as targets for SMA therapy
The 3′ strands of adjacent stems ISTL1, ISTL2 and ISTL3 are formed by the deep intronic 
sequence from positions 275 to position 297, we called this sequence ISS-N2 (Figs. 1 & 5). 
Located far away from the 5′ss, ISS-N2 emerged as a unique sequence engaged in formation 
of three adjacent structures. Underscoring the inhibitory role of ISS-N2, deletions within 
ISS-N2 stimulated SMN2 exon 7 inclusion.46 Therefore, we evaluated ISS-N2 as a potential 
target for an ASO-mediated splicing correction in SMA patient cells.
ISS-N2-targeting ASOs stimulate SMN2 exon 7 inclusion
We employed SMA-patient-derived GM03813 cell line to test whether blocking of ISS-N2 
by ASOs will have a positive effect on SMN2 exon 7 splicing. GM03813 cells contain only 
SMN2 and have been widely used to test the efficacy of compounds in modulating exon 7 
splicing. Our exploratory experiments were performed with propriety-free RNA ASOs 
containing phosphorothioate backbone and 2′-O-methyl modifications at every sugar 
residue. To minimize the off-target effect, we performed experiments at low nM ASO 
concentrations. Among eight ASOs tested, ASO 283-297 that sequestered the 3′ strands of 
ISTL1 and ISTL2 led to a substantial inclusion of SMN2 exon 7 (Fig. 5).46 Consistent with 
the increase in exon 7 inclusion, ASO 283-297 elevated the levels of SMN and SMN-
interacting protein Gemin2. These results validated that a deep intronic sequence associated 
with an inhibitory structure formed by a LDI could serve as a potential target for SMA 
therapy.
Mechanism of ISS-N2-targeting ASO
Stimulation of SMN2 exon 7 splicing by ASO 283-297 could occur through a combinatorial 
effect leading to the enhanced recruitment of U1 snRNP at the 5′ ss of exon 7. Indeed, a 
recent report suggests a multitude of interactions at the 5′ ss of exon 7.65 Annealing of ASO 
283-297 to its target disrupts ISTL1 and ISTL2 freeing the 5′ ss for interactions with U1 
snRNP and rendering URC1 and URC2 accessible for binding by TIA1, which is known to 
recruit U1 snRNP to weak 5′ ss. Therefore, simultaneous disruption of ISTL1 and ISTL2 is 
likely to have additive or synergistic effect on the recruitment U1 snRNP to the 5′ ss of exon 
7. Consistent with this hypothesis, ASO 290-307 that disrupted ISTL1 but not ISTL2 
produced a lesser stimulatory effect on SMN2 exon 7 splicing (Fig. 5). Similarly, ASO 
276-290 that disrupted ISTL2 but not ISTL1 had a smaller stimulatory effect on SMN2 exon 
7 splicing (Fig. 5). It appears that the structural context set by TSL2, ISTL1, TSL3 and 
ISTL2 at the 5′ ss of exon 7 is designed to facilitate recruitment of negative regulators (such 
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as hnRNP A1/A2B1) that somehow communicate with the factors interacting with C6U and 
A100G. This line of thoughts is consistent with the intron definition model that we recently 
proposed for the regulation of SMN exon 7 splicing.66 Unlike exon definition model that 
puts special emphasis on cis-elements within exon and flanking intronic sequences, intron 
definition model relies on regulatory sequences and structures within the entire intron. 
However, intron definition model is not complete till we fully understand how the 5′ ss of 
exon 7 communicates with the 3′ ss of exon 8. Similarly, we need to uncover the mechanism 
of by which pairing between the 5′ ss of exon 6 and the 3′ ss of exon 7 occurs. Reports that 
ASOs targeting Element 1 in intron 6 could stimulate SMN2 exon 7 underscores the role of 
intronic sequences upstream of exon 7.67 Further experiments are likely to uncover the role 
of additional intronic structures and transacting factors that will refine our understanding of 
the known interactions and reveal additional therapeutic targets.
Future perspectives
The biological role of SMN2, a gene specific to humans, remains elusive. Presence of SMN2 
in humans is attributed to SMN gene duplication about 5 million years ago followed by a 
recent gene conversion that happened after human-chimpanzee divergence.68 No doubt, 
SMN2 serves as a promising target for SMA therapy by compounds that elevate the levels of 
SMN by enhancing SMN2 transcription and/or by correcting SMN2 exon 7 splicing. SMN2, 
which contributes towards the overall cellular pool of SMN, is likely to impact the severity 
of other neurodegenerative diseases. For instance, low SMN level in SMA has been found to 
downregulate α-synuclein, a protein associated with Parkinson’s disease.69 Several lines of 
evidence suggests that SMN modulates severity of Amyotrophic Lateral Sclerosis 
(ALS).70,71 We serendipitously discovered deletion of SMN2 in a patient cell line of Batten 
disease (BD).72 However, the significance of this finding is yet to be determined. The 
distinct splicing pattern of SMN2 under the conditions of oxidative stress makes SMN2 a 
stress sensing gene.72 Oxidative stress is a mediator of life history trade-offs.73 Therefore, 
SMN2 may have gained a role of a sensor that alerts and prepares the system for a better 
survival during stress-associated conditions.
Although skipping of SMN2 exon 7 is linked to the existing C6U and A100G mutations, 
many regulatory elements and transacting factors not associated with these positions have 
been reported.65 The antisense drug (ISIS-SMNRX based on ISS-N1 target) currently under 
phase 3 clinical trial, provides an undisputable proof that the desired splicing modulation 
could be achieved through intronic sequences.55 We and others have previously considered 
ISS-N1 as a portable linear cis-element, sequestration of which by an ASO produces the 
stimulatory effect (on SMN2 exon 7 splicing) by displacing a negative interacting factor. 
However, our recent finding of 10C-mediated LDI challenges this simplistic line of thoughts 
and supports the hypothesis that an ISS-N1-targeting ASO perturbs the inhibitory ISTL1 as 
well as makes the binding site of TIA1 accessible. Both, destabilization of ISTL1 and 
accessibility of TIA1 binding sites is conducive for the recruitment of U1 snRNP at the 5′ ss 
of exon 7. Similar outcome is expected to be produced by targeting ISS-N2 located in the 
middle of intron 7.
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While our finding of the unique LDI that involves the deep intronic sequence is a major step 
forward towards understanding the mechanism of aberrant splicing in SMA, its implications 
go beyond SMA. A recent report connects an abrogation of an LDI within intron 3 of 
proteolipid protein 1 (PLP1) gene with X-linked leukodystrophy Pelizaeus-Merzbacher 
disease (PMD).74 This finding is just the tip of the iceberg as origins of many more genetic 
disorders associated with intronic mutations are yet to be established. LDIs could be loosely 
defined as high-order RNA structures formed with the help of secondary RNA structures. 
Although complementary sequences are the driving force of a LDI, a role of transacting 
factors in the formation and/or stabilization of a LDI could not be ruled out. In certain cases, 
a LDI could be enforced solely through protein-protein interactions.75 Now that we are 
beginning to appreciate the significance of intronic LDIs as the basis of diseases and their 
therapy, the stage is set for future studies to uncover the critical information present in 
secondary and high-order intronic structures that occupy a large portion of our 
transcriptome.
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Figure 1. 
Diagrammatic representation of cis-elements for SMN exon 7 splicing. (A) Secondary 
structure of SMN2 of exon 7 based on enzymatic probing.24 Numbering starts from the 
beginning of exon 7. (B) Diagrammatic representation of cis-elements within exon 7. 
Numbering starts from the beginning of exon 7. Positive and negative cis-elements/
transacting factors are indicated by (+) and (−), respectively. Exinct (Extended inhibitory 
context), Conserved tract and 3′-Cluster were identified by in vivo selection.25 Binding sites 
for SF2/ASF, hnRNP A1, hnRNP A2/B1, Sam 68, hnRNP Q, Tra2-β1, hnRNP G, hnRNP M 
and PSF described elsewhere.26–36 G-to-C mutation at position 25 (G25C) in SMN2 exon 7 
has been shown to modify the severity of SMA.37–39 (C) Diagrammatic representation of 
cis-elements within intron 6. Nucleotides of intron 6 and exon 7 are shown in lower case and 
capital letters, respectively. Numbering starts from the beginning of exon 7. Location of 
Element 1 is highlighted in red.40 PTB and FUSE-BP interact with Element 1.41 A binding 
site of the stimulatory hnRNP C1/C2 is indicated.42 (D) Diagrammatic representation of cis-
elements within intron 7. Numbering starts from the beginning of intron 7. Positive and 
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negative cis-elements are indicated by (+) and (−), respectively. The 5′ ss of exon 7 is 
highlighted in blue. ISS-N1, the overlapping GC-rich sequence as well as 10C and LS-1 that 
are engaged in LDI with each other, all contribute to skipping of exon 7.43–46 ISS-N1 
harbors two putative hnRNP A1/A2B1 binding sites.47 An A100G substitution creates a 
binding site for hnRNP A1.23 Element 2 and U-rich clusters (URC1 and URC2) are positive 
cis-elements.48, 49 Stimulatory factor TIA1 interacts through URC1 and URC2.49 ISS-N2 is 
a structure-associated inhibitory element located in the 3′ half of intron 7.46
Singh et al. Page 14
Ann N Y Acad Sci. Author manuscript; available in PMC 2016 April 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 2. 
Intronic sequences involved in LDI. (A) Diagrammatic representation of F14 and L14 
binding sites within ISS-N1. Relative positioning of ISS-N1, GCRS, LS-1 and ISTL1 are 
shown. (B) Effect of F14 and L14 on SMN2 exon 7 splicing. Experiments were done using 
SMN2 minigenes.45 Sites of intronic deletions are shown by dotted lines (top panel). Bottom 
panel shows loss of inhibitory effect of L14 due to a 3-nt deletion that abrogates ISTL1.
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Figure 3. 
Structure of SMN2 intron 7 deduced by chemical probing, using SHAPE. Positions of LS-1, 
ISTLs, TSLs and binding sites of hnRNP A1/A2B1 and TIA1 are shown. ISS-N2 is 
comprised of 3′ strands of ISTL1, ISTL2 and ISTL3.46 Numbering starts from the beginning 
of intron 7.
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Figure 4. 
The 3D structure models at the 5′ ss of exon 7 based on the SHAPE derived secondary 
structure of intron 7. The predicted 3D conformations and tertiary structures are modeled on 
chemical structure probing and not defined by experimental constraints.46 (A) The probed 
secondary structure (left panel) and the predicted 3D structure model (right panel) of the 
wild type 5′ ss of exon 7. 3D Model was predicted using the RNA assembly application 
within the Rosetta modeling suite.64 Numbering starts from the beginning of intron 7 at G1 
with a rainbow color scheme ranging from blue at the 5′ end to red at the 3′ end. Relative 
positioning of TSL2 (residues −17 to 2), TSL3 (residues 17 to 41), ISTL1 (residues 3 to 10 
and 290 to 297) and ISTL2 (residues 50 to 56 and 283 to 289) are shown. The TSL3 stem is 
extended by mismatched base pairing (residues 12 to 16 and 42 to 46), which is not defined 
by experimental data and may be transient. Model shows a sequestered 5′ ss that is not 
favorable for the recruitment of U1 snRNP. (B) The probed secondary structure (left panel) 
and the 3D structure model (right panel) of the 5′ ss of exon 7 in the presence of F14. Model 
was predicted similarly as described for the wild type context in section A. F14 is 
highlighted in magenta with the 5′ and 3′ ends indicated. The retained secondary structural 
elements are labeled, which includes TSL2 (residues −17 to 2) and ISTL2 (residues 50 to 56 
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and 283 to 289). The stem region of ISTL2 is extended by mismatch base pairing (residues 
42 to 49 and 290 to 298) and an internal bulge (C291). Model shows an accessible 5′ ss that 
is favorable for the recruitment of U1 snRNP. (C) The probed secondary structure (left 
panel) and the 3D structure model (right panel) of the 5′ ss of exon 7 in the presence of L14. 
Model predictions and labeling details are the same as described in section B. Model shows 
a sequestered 5′ ss that is not favorable for the recruitment of U1 snRNP.
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Figure 5. 
ISS-N2 as a target for splicing correction in SMA. (A) Left panel shows diagrammatic 
representation of ISS-N2 target and ASOs annealing positions, whereas, right panel shows 
the effect of ASOs on SMN2 exon 7 splicing in SMA patient cells. Experimental details and 
results have been described elsewhere.46 (B) Proposed mechanism by which ASO 283-297 
promotes exon 7 inclusion. ASO 283-297 disrupts ISTL1 and ISTL2, leading to binding of 
TIA1 and enhanced recruitment of U1 snRNP.
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